Themis Medicare launches novel transdermal Estradiol spray Lenzetto in Indian market

04 Jan 2023 Evaluate

Themis Medicare has launched a novel transdermal Estradiol spray Lenzetto in the Indian market for treatment of Menopausal Symptoms. Lenzetto has a clinical experience in 40 countries and is approved by USFDA & EMA for the treatment of Menopausal Symptoms. Lenzetto is manufactured in Europe by Gedeon Richter, The Global Innovators in Women’s Health. 

Lenzetto a novel transdermal estradiol with Metered Dose Transdermal Spray (MDTS) Technology) delivers therapeutic doses of estradiol to the skin, using a metering pump containing 1.53 mg/spray estradiol hemihydrate. Transdermal delivery of estrogen is well established in clinical practice and ensures sufficient serum estradiol levels to alleviate Menopausal Symptoms like hot flashes, night sweats etc. at lower overall estradiol exposure while avoiding some of the consequences of high hepatic exposure and first-pass metabolism.

Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.

Themis Medicare Share Price

105.60 -0.70 (-0.66%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×